TIA1 variant drives myodegeneration in multisystem proteinopathy with SQSTM1 mutations

Youjin Lee
Washington University School of Medicine in St. Louis

Robert C. Bucelli
Washington University School of Medicine in St. Louis

Conrad C. Weihl
Washington University School of Medicine in St. Louis

et al

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
https://digitalcommons.wustl.edu/open_access_pubs/6647
TIA1 variant drives myodegeneration in multisystem proteinopathy with SQSTM1 mutations


Multisystem proteinopathy (MSP) involves disturbances of stress granule (SG) dynamics and autophagic protein degradation that underlie the pathogenesis of a spectrum of degenerative diseases that affect muscle, brain, and bone. Specifically, identical mutations in the autophagic adaptor SQSTM1 can cause varied penetrance of 4 distinct phenotypes: amyotrophic lateral sclerosis (ALS), frontotemporal dementia, Paget’s disease of the bone, and distal myopathy. It has been hypothesized that clinical pleiotropy relates to additional genetic determinants, but thus far, evidence has been lacking. Here, we provide evidence that a TIA1(p.N357S) variant dictates a myodegenerative phenotype when inherited, along with a pathogenic SQSTM1 mutation. Experimentally, the TIA1-N357S variant significantly enhances liquid-liquid-phase separation in vitro and impairs SG dynamics in living cells. Depletion of SQSTM1 or the introduction of a mutant version of SQSTM1 similarly impairs SG dynamics. TIA1-N357S-persistent SGs have increased association with SQSTM1, accumulation of ubiquitin conjugates, and additional aggregated proteins. Synergetic expression of the TIA1-N357S variant and a SQSTM1-A390X mutation in myoblasts leads to impaired SG clearance and myotoxicity relative to control myoblasts. These findings demonstrate a pathogenic connection between SG homeostasis and ubiquitin-mediated autophagic degradation that drives the penetrance of an MSP phenotype.

Introduction

Pathogenic mutations in some genes lead to a spectrum of variably penetrant phenotypes that span different organs and post-mitotic tissue (1–4). For example, the same mutation in the autophagic adaptor protein SQSTM1 (also known as p62) can cause Paget’s disease of the bone (PDB), rimmed vacuolar inclusion body myopathy (RV-IBM), amyotrophic lateral sclerosis (ALS), or frontotemporal dementia (FTD) (1). The term multisystem proteinopathy (MSP) has become useful to describe this growing family of genetic diseases that so far have been reported to have dominant mutations in the pleiotropic genes VCP, HNRNPA2B1, HNRNPA1, and SQSTM1 (1–4). Other disease-associated genes with variably penetrant phenotypic expression of RV-IBM, ALS, and FTD, yet no association with PDB, include TIA1 and MATR3 (5–7). One distinctive feature of the MSP pedigrees is that patients with the same mutation, and even the same mutation within a family, can manifest different phenotypes (i.e., PDB in 1 sibling and ALS in another sibling). MSP also unifies 2 key pathologic features in affected tissue: ubiquitinated aggregates and the accumulation of RNA-binding proteins with low-complexity sequence domains (LCDs) such as TDP-43 (4).

Mutations in several proteins that facilitate ubiquitin-dependent autophagy such as VCP, SQSTM1, UBQLN2, and OPTN are associated with PDB, RV-IBM, ALS, and FTD (1, 2, 8, 9). Disease mutations in these proteins impair the degradation and clearance of ubiquitinated inclusions, resulting in their accumulation. SQSTM1 is an autophagic adaptor protein with a UBA domain and an autophagosome-interacting motif (10). Most pathogenic variants in SQSTM1 are missense mutations within or truncations of the UBA domain (11). These mutations affect the oligomeriza-
tion of SQSTM1 and its ability to recruit ubiquitinated aggregates to the autophagosome, suggesting that the pathogenesis of MSP and its related diseases are due in part to alterations in protein homeostasis and particularly to autophagic degradation of ubiquitinated proteins in vulnerable tissues (11). One disease-associated SQSTM1 mutation that has been demonstrated to cause the full spectrum of MSP phenotypes (PDB, RV-IBM, ALS, and FTD) is a proline-to-leucine mutation at residue 392 (P392L) in the UBA domain (12-15). This single mutation is the most common genetic cause of PDB but is incompletely penetrant, suggesting that other genetic or environmental factors are needed for the phenotypic manifestation of PDB, RV-IBM, ALS, or FTD (16).

One distinctive pathologic feature seen in MSP-affected tissues is the accumulation of cytoplasmic inclusions of RNA-binding proteins such as TDP-43 (4). Indeed, mutations in RNA-binding proteins with LCDs, including TARDBP, FUS, HNRNPA2B1, HNRNPA1, TIA1, and HNRNPD1, cause dominantly inherited forms of MSP, ALS, FTD, and RV-IBM (3, 6, 7, 17-19). These RNA-binding proteins promote the assembly of membrane-less organelles such as stress granules (SGs) through the biophysical process of liquid-liquid phase separation (LLPS) that is mediated via the LCD (20). Importantly, disease-causing mutations in the LCD of these RNA-binding proteins alter their biophysical properties, increase their propensity to undergo LLPS, and result in the accumulation of poorly dynamic SGs that are believed to underlie cellular dysfunction and evolve into the pathological inclusions characteristic of these diseases (7, 20, 21). Notably, TIA1 is a key component of cytosolic SGs (7). Dominantly inherited mutations within the LCD of TIA1 cause MSP or more discreet clinical manifestations of either ALS-FTD or a distinctive form of distal myopathy termed Welander distal myopathy (WDM) (6, 7). As with hRNPA1, hRNPA2B1, and TDP-43, disease mutations in the LCD of TIA1 alter its biophysical properties, promote LLPS, enhance fibrillization, and impair SG clearance as a mechanism of their pathogenicity (6, 7).

RV-IBMs are defined by a core set of pathologic features including rimmed vacuoles (RVs) and inclusion bodies, seen in degenerative myopathies (22). RVs are present within some myofibers and contain autophagic and membranous debris, such as SQSTM1 and MAPIICl3. Many proteins have been observed to accumulate as inclusions in RV-IBM tissue. These proteins include ubiquitin, β-amyloid, and TDP-43, with TDP-43 aggregation being specific for RV-IBMs (22). In many cases, protein inclusions and vacuolar debris are stained by Congo red and show birefringence, suggesting that the inclusions contain amyloidogenic proteins. A number of studies now establish that SQSTM1 and/or TDP-43 within myofibers serve as markers of muscle degeneration in RV-IBMs (23-26).

The relationship between SG homeostasis and autophagic protein degradation has been demonstrated in cell cultures (27, 28). Specifically, autophagy participates in SG clearance. Autophagy-mediated SG clearance may also require the ubiquitin segregate VCP (27, 28). Autosomally dominantly inherited mutations in VCP cause MSP, but whether the pathogenesis of MSP is mediated via its effect on SG homeostasis is not known (2). The present study identifies a rare variant in TIA1 that dictates the tissue specificity associated with SQSTM1 mutations. Digenic inheritance of a TIA1-N357S variant with a pathogenic SQSTM1 mutation causes a distal myopathy with RV-IBM pathology. This finding connects SG homeostasis with ubiquitin-dependent autophagic degradation as a key mediator of the phenotypic outcome within the spectrum of RV-IBM, ALS, and FTD and shows the relevance of oligogenic mechanisms as one cause of neurodegenerative-neuromuscular disease.

**Results**

Digenic inheritance of an MSP-associated SQSTM1 mutation with a rare TIA1-N357S variant occurs in distal myopathy patients with RV pathology. We have previously described 2 unrelated families with distal myopathy and RV-IBM pathology caused by a c.1165+1 G>A splice donor variant in SQSTM1 (1). This variant generates a truncated SQSTM1 protein that lacks its UBA domain and has been identified in patients with PDB and ALS (12, 13). Subsequent to this discovery, we identified an additional 3 patients with distal myopathy and a SQSTM1 p.P392L variant (15). Likewise, this SQSTM1 p.P392L variant has been associated with dominantly inherited PDB, ALS, and FTD, phenotypes that were not present in our patients (12-14). Interestingly, these 3 patients had been previously identified in our cohort of distal myopathy patients carrying a rare TIA1 c.1070A>G; p.N357S; rs116621885 variant with a minor allele frequency (MAF) of 0.007. Surprisingly, our 3 previously reported SQSTM1 c.1165+1 G>A patients also carried the same rare TIA1 p.N357S variant. Dominant mutations in TIA1 are associated with WDM, a distal myopathy with RV-IBM pathology and, more recently, with ALS and FTD (6, 7). Notably, like with the WDM- and ALS-FTD-associated TIA1 mutations, the TIA1 p.N357S variant was present within the LCD at conserved residues (Figure 1A).

We used 2 approaches to identify additional myopathy patients with SQSTM1 mutations and the TIA1 p.N357S variant. First, we analyzed our neuromuscular disease gene panel sequencing results that included SQSTM1 and TIA1 for 1,294 patients with a presumed hereditary muscle disease (15). In addition, we performed Sanger sequencing of SQSTM1 in 14 patients with undetermined distal myopathy and a WDM phenotype, whom we had previously identified as having the TIA1 p.N357S variant. These approaches identified a total of 8 patients from 6 families with the common SQSTM1 p.P392L mutation, 7 of whom also carried the TIA1 p.N357S variant. Notably, none of them had PDB, and all had distal myopathy with RV-IBM pathology, with the exception of 1 patient, who carried only the SQSTM1 p.P392L mutation without the TIA1 p.N357S variant. This patient had a proximal phenotype, without RV-IBM muscle pathology, that had been characterized as limb-girdle muscular dystrophy.

We also identified 3 patients from 2 families with a previously reported SQSTM1 p.M404V mutation that was associated with PDB and dementia (29, 30). These patients also carried the TIA1 p.N357S variant and had late-onset, distal predominant myopathy with RV-IBM pathology and no evidence of PDB. One additional patient with distal myopathy and RV-IBM pathology carried the TIA1 p.N357S variant and a rare synonymous SQSTM1 variant, c.1083C>T; p.S361S, which was previously identified in a patient with early-onset dementia (30). This synonymous mutation has a MAF of 0.00008 and is predicted to be disease causing.

MRI of patients’ lower extremities revealed extensive fatty degenerative changes in distal muscles, evidenced by focal involvement of lower leg gastrocnemius and soleus muscles (Figure 1C). Muscle biopsies from a patient showed variation in fiber...
1166
The Journal of Clinical Investigation

p. P392L or a SQSTM1 p.M404V mutation and a TIA1 p.N357S variant, whereas family members carrying only a TIA1 p.N357S variant were unaffected (Figure 1B).

Importantly, sequencing of 50 patients (26 male, 24 female; average age, 73.7 ± 7.3 years) with previously reported pathogenic SQSTM1 mutations, including 40 patients with a SQSTM1-P392L mutation and 2 with a SQSTM1-M404V mutation manifesting with PDB but no muscle weakness, did not reveal any TIA1-N357S variant, supporting the idea that both variants are necessary for a muscle phenotype with RV-IBM pathology (Supplemental Table 1) (31).

TIA1 N357S variant is overrepresented in distal myopathy patients. Although patients in these small pedigrees with only the TIA1 p.N357S variant had no evidence of weakness, we reasoned that the rare TIA1 p.N357S variant may itself be enriched in patients with a distal myopathy phenotype. Indeed, in our large sequencing proj-

Figure 1. Digenic inheritance of SQSTM1 and TIA1 variants leads to distal myopathy with RV-IBM pathology. (A) Linear diagram of the TIA1 protein highlighting conserved regions of the LCD. Distal myopathy–associated variant positions are shown in yellow and ALS and FTD variants in blue. (B) Pedigrees of families IV, VII, and IX showing segregation. DNA was only available for the patients indicated with an asterisk. (C) Muscle imaging findings for patient V-2 at age 54 years. Severe involvement of all calf muscles was seen on MRI T1-weighted images. The solid white arrow indicates normal muscle, and the arrowhead indicates atrophic muscle with fatty replacement. (D) H&E staining of a muscle biopsy of the right tibialis from patient XII-1 showing several fibers with RVs (arrows). Original magnification, 50 μm. (E) Immunofluorescence staining of TIA1 (red) with SQSTM1 (green in upper panel) or TDP-43 (green in lower panel) revealed accumulation and partial colocalization of these proteins in the muscle biopsy from patient V-2. Both sets of images show a RV fiber. The dotted lines denote affected fiber. Scale bars: 50 μm.
The allele frequency 0.1 for distal myopathy. A similar overrepresentation of this \textit{TIA1} p.N357S variant was seen in 5 patients from a second cohort of 51 patients with undiagnosed myopathy revealed by whole-exome sequencing. All 5 patients had a distal predominant phenotype with RV-IBM pathology, and 2 of these patients had an additional c.1165+1 G>A splice donor variant in \textit{SQSTM1} (1).

Table 1. Clinical characteristics of the patients

<table>
<thead>
<tr>
<th>Family</th>
<th>Sex</th>
<th>Age</th>
<th>Onset</th>
<th>Weakness</th>
<th>CK</th>
<th>EMG</th>
<th>Biopsy</th>
<th>Muscle imaging</th>
<th>Pagets/dementia</th>
<th>SQSTM1</th>
<th>TIA1</th>
</tr>
</thead>
<tbody>
<tr>
<td>I-1*</td>
<td>Male</td>
<td>63</td>
<td>52</td>
<td>+</td>
<td>419</td>
<td>myopathic</td>
<td>RVs, myofibrillar disarray</td>
<td>NA</td>
<td>–/–</td>
<td>c.1165+1 G&gt;A; p.Glu398delAspLysTer</td>
<td>c.1070A&gt;G; p.N357S</td>
</tr>
<tr>
<td>I-2*</td>
<td>Male</td>
<td>47</td>
<td>42</td>
<td>+</td>
<td>143</td>
<td>myopathic</td>
<td>ND</td>
<td>NA</td>
<td>–/–</td>
<td>c.1165+1 G&gt;A; p.Glu398delAspLysTer</td>
<td>c.1070A&gt;G; p.N357S</td>
</tr>
<tr>
<td>II-1*</td>
<td>Male</td>
<td>60</td>
<td>50</td>
<td>–</td>
<td>346</td>
<td>myopathic</td>
<td>RVs, myofibrillar disarray</td>
<td>TA, Gmed, S</td>
<td>–/–</td>
<td>c.1165+1 G&gt;A; p.Glu398delAspLysTer</td>
<td>c.1070A&gt;G; p.N357S</td>
</tr>
<tr>
<td>III-1*</td>
<td>Male</td>
<td>65</td>
<td>35</td>
<td>–</td>
<td>NA</td>
<td>NA</td>
<td>RVs</td>
<td>TA, EDL/EHL, Gmed, Glat, S</td>
<td>–/–</td>
<td>c.1175C&gt;T; p.P392L</td>
<td>c.1070A&gt;G; p.N357S</td>
</tr>
<tr>
<td>IV-1</td>
<td>Female</td>
<td>68</td>
<td>NA</td>
<td>+</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>–/–</td>
<td>c.1175C&gt;T; p.P392L</td>
<td>c.1070A&gt;G; p.N357S</td>
</tr>
<tr>
<td>V-2</td>
<td>Female</td>
<td>57</td>
<td>45</td>
<td>– (+?)</td>
<td>2\times UNL</td>
<td>NA</td>
<td>RVs</td>
<td>Gmed, Glat, S, peronei</td>
<td>–/–</td>
<td>c.1175C&gt;T; p.P392L</td>
<td>c.1070A&gt;G; p.N357S</td>
</tr>
<tr>
<td>VI-1</td>
<td>Male</td>
<td>69</td>
<td>50</td>
<td>–</td>
<td>3\times UNL</td>
<td>myopathic/neurogenic (PNP)</td>
<td>RVs</td>
<td>TA, Gmed, Glat</td>
<td>–/–</td>
<td>c.1175C&gt;T; p.P392L</td>
<td>c.1070A&gt;G; p.N357S</td>
</tr>
<tr>
<td>VII-1</td>
<td>Male</td>
<td>50</td>
<td>48</td>
<td>–</td>
<td>2\times UNL</td>
<td>myopathic</td>
<td>RVs</td>
<td>TA, Gmed, Glat, S, glutel, paraspinal</td>
<td>–/–</td>
<td>c.1175C&gt;T; p.P392L</td>
<td>c.1070A&gt;G; p.N357S</td>
</tr>
<tr>
<td>VIII-1</td>
<td>Female</td>
<td>69</td>
<td>45</td>
<td>+</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>–/–</td>
<td>c.1175C&gt;T; p.P392L</td>
<td>c.1070A&gt;G; p.N357S</td>
</tr>
<tr>
<td>XI-1</td>
<td>Male</td>
<td>74</td>
<td>68</td>
<td>–</td>
<td>1.5 \times UNL</td>
<td>myopathic</td>
<td>RVs, myofibrillar disarray</td>
<td>Asymmetric TA, S, Gmed</td>
<td>–/–</td>
<td>c.1083C&gt;T; p.S361S</td>
<td>c.1070A&gt;G; p.N357S</td>
</tr>
<tr>
<td>XII-1</td>
<td>Female</td>
<td>54</td>
<td>40</td>
<td>–</td>
<td>NA</td>
<td>myopathic</td>
<td>NA</td>
<td>All lower leg muscles except left Glat, deep toe flexors</td>
<td>–/–</td>
<td>–</td>
<td>c.1070A&gt;G; p.N357S homozygous</td>
</tr>
</tbody>
</table>

EDL/EHL, long toe extendors; Gmed, gastrocnemius medialis; Glat, gastrocnemius lateralis; NA, not available; ND, not done; PNP, polyneuropathy; S, soleus; TA, tibialis anterior; UNL, upper normal limit. Previously reported patients from *ref. 1 and *ref. 15.

ect involving 1,293 patients with presumed hereditary myopathy, 41 patients (3%) had the N357S variant (allele frequency 0.0162 vs. 0.007 in the general population), and when this was stratified to those with a distal myopathy phenotype involving upper limbs as well, 17 of 86 (20%) of these patients carried the variant, including 1 patient who was homozygous for the \textit{TIA1} p.N357S variant, making
to a lower protein concentration, indicating an increased propensity of mutant TIA1 to phase separate as a result of stronger intermolecular protein-protein interactions (Figure 2A). Although the promotion of LLPS with TIA1-EK was associated with an increased rate of amyloid-like fibril formation, as demonstrated by a time-dependent increase in thioflavin-T incorporation when compared with TIA1-WT, we did not see this increase with purified TIA1-NS (Figure 2B).

**The TIA1-N357S variant promotes LLPS and impairs SG clearance.**

To examine the impact of the TIA1-N357S (NS) mutation on LLPS, we constructed a phase diagram by measuring the coexistence line of a protein-depleted light phase and a protein-enriched dense phase as a function of temperature and protein concentration. Like the previously characterized TIA1-E384K (EK) mutant, the TIA1-NS mutation caused a significant leftward shift in the coexistence line to a lower protein concentration, indicating an increased propensity of mutant TIA1 to phase separate as a result of stronger intermolecular protein-protein interactions (Figure 2A). Although the promotion of LLPS with TIA1-EK was associated with an increased rate of amyloid-like fibril formation, as demonstrated by a time-dependent increase in thioflavin-T incorporation when compared with TIA1-WT, we did not see this increase with purified TIA1-NS (Figure 2B).
The effect of TIA1-NS and -EK variants on LLPS in vitro suggested that these variants might affect the dynamics of SGs in vivo. To test this hypothesis, we expressed GFP-TIA1-WT, -NS, or -EK in mouse embryonic fibroblasts (MEFs) for 24 hours. Immunoblotting confirmed similar levels of expression for GFP-TIA1-WT, -NS, and -EK (Supplemental Figure 2A). MEFs expressing GFP-TIA1 were fixed and stained with the SG marker G3BP1. Untreated GFP-TIA1-WT–expressing cells did not form SGs, while some SGs were detected in GFP-TIA1-NS– or -EK–expressing cells (Figure 2, C and D). Heat shock (HS) at 42°C induced SG formation in MEFs expressing GFP-TIA1-WT, -NS, or -EK and immunostained with SQSTM1 antibody following incubation at 42°C for 1 hour and reincubation at 37°C for the indicated durations. (D) Bar graph of the percentage of GFP-TIA1/SQSTM1-positive SGs in C. Individual GFP-TIA1 SGs were counted and are indicated as the total number of SGs. Representative data were pooled from 3 independent experiments (n = 800–1000). Scale bars: 5 μm. Error bars represent the mean ± SEM. (B and D) *P < 0.05 by 2-way ANOVA and 2-tailed Student’s t test.

The effect of TIA1-NS and -EK variants on LLPS in vitro suggested that these variants might affect the dynamics of SGs in vivo. To test this hypothesis, we expressed GFP-TIA1-WT, -NS, or -EK in mouse embryonic fibroblasts (MEFs) for 24 hours. Immunoblotting confirmed similar levels of expression for GFP-TIA1-WT, -NS, and -EK (Supplemental Figure 2A). MEFs expressing GFP-TIA1 were fixed and stained with the SG marker G3BP1. Untreated GFP-TIA1-WT–expressing cells did not form SGs, while some SGs were detected in GFP-TIA1-NS– or -EK–expressing cells (Figure 2, C and D). Heat shock (HS) at 42°C induced SG formation in MEFs expressing GFP-TIA1-WT, -NS, or -EK after 1 hour. Upon return to 37°C for 30 minutes, approximately 10% of GFP-TIA1-WT–expressing MEFs contained SGs as compared with approximately 40% of MEFs expressing GFP-TIA1-NS or -EK (Figure 2, C and D). TIA1 in SGs is normally in rapid equilibrium with TIA1 in the surrounding cytoplasm. We investigated whether TIA1-NS mutation affects its mobility within SGs. MEFs expressing GFP-TIA1-WT, -NS, or -EK were treated with 0.5 mM arsenite (AsIII) for 1 hour, and GFP-TIA1 SGs were subjected to fluorescence recovery after photobleaching (FRAP). Following photobleaching, approximately 65% of GFP-TIA1-WT fluorescence rapidly recovered, whereas GFP-TIA1-NS and -EK showed approximately 40% and 60% recovery, respectively (Figure 2E and Supplemental Figure 2B).

SQSTM1 is necessary for SG homeostasis. To explore the role of SQSTM1 in SG formation and clearance, we immunostained endogenous TIA1 and G3BP1 in control MEFs and MEFs lacking SQSTM1 (p62−/−) (Figure 3, A and B). Untreated control or p62−/− MEFs did not form SGs. Following incubation at 42°C for 1 hour and reincubation at 37°C for the indicated durations, approximately 95% of control MEFs and 70% of p62−/− MEFs contained SGs (Figure 3, A and B). Twenty minutes after reincubating the cells at 37°C, approximately 50% of the SGs disappeared in the control MEFs and ultimately dissipated by 1 hour. In contrast, p62−/− MEFs had a slower SG clearance, with some cells maintaining SGs after 180 minutes (Figure 3, A and B). Persistent TIA1-positive SGs in p62−/− MEFs coimmunolocalized with an antibody that recognizes ubiquitin conjugates (Supplemental Figure 3A). Consistent with SQSTM1 mediation of the clearance of SGs...
via an autophagy-lysosomal pathway, we found that incubation of p62−/− MEFs with the lysosomal inhibitor bafilomycin A during HS recovery did not further augment the decrease in SG clearance seen with loss of SQSTM1 (Supplemental Figure 3B).

To determine whether there is a direct connection between TIA1 and SQSTM1, we immunostained for endogenous SQSTM1 in MEFs expressing GFP-TIA1-WT, -NS, or -EK after 1 hour of HS and following a 30-minute HS recovery to 37°C for 30 minutes. Individual TIA1 SGs (green) were counted and are indicated as the total number of TIA1 SGs. Representative data were pooled from 3 independent experiments (n = 350–450). (C) IF images of MEFs expressing GFP-TIA1-WT, -NS, or -EK and labeled with Alexa Fluor 594–azide (red) to detect DRiPs before HS, after incubation at 42°C for 1 hour, and following a 30-minute HS recovery period. Representative data were pooled from 3 independent experiments (n = 350–450). (D) Bar graph of the percentage of TIA1 SGs labeled with DRiPs as in C. Individual TIA1 SGs (green) were counted and are indicated as the total number of TIA1 SGs. *P < 0.05 by 2-way ANOVA and 2-tailed Student’s t test.
30-minute HS recovery, MEFs expressing mCherry-SQSTM1-PL, -MV, or -AX had persistent SGs in 80% of cells, suggesting that disease-associated SQSTM1 mutations delay SG clearance (Figure 6A).

To explore the synergy of a SQSTM1 disease mutation and the TIA1-N357S variant, we used patient-derived fibroblasts from 2 control patients (fibroblast lines 112 and 409), 2 patients carrying the TIA1-N357S variant (fibroblast lines 107 and 319), and 1 patient carrying both SQSTM1 c.1165+1 G>A mutations, which generate a truncated SQSTM1-A390X mutation and a TIA1-N357S variant (fibroblast line 483). We treated low-passage fibroblasts with 0.5 mM AsIII for 1 hour and then replaced AsIII-containing media for 40 minutes. Fibroblasts were immunostained for endogenous TIA1 and G3BP1. Untreated fibroblasts had no detectable SGs. Following 1 hour of AsIII treatment, all fibroblasts formed TIA1/G3BP1-positive SGs (Figure 6, B and C). These SGs dissipated in all fibroblasts but were significantly increased in fibroblast line 483, which contained both disease variants (Figure 6, B and C).

Coexpression of MSP-associated SQSTM1 mutations and TIA1-N357S is myotoxic. To see whether the synergistic effect of SQSTM1 mutations and TIA1 variants occurred in muscle cells, we cotransfected C2C12 myoblasts with plasmids expressing mCherry-SQSTM1-WT or mCherry-SQSTM1 carrying an MSP mutation (PL, MV, or AX) and GFP-TIA1-WT or GFP-TIA1 carrying a distal myopathy variant (EK or NS). After 60 minutes of HS, approximately 100% of myoblasts had TIA1-GFP–positive SGs, regardless of the mutation or variant (Figure 6D). In contrast, after 60 minutes of HS recovery, myoblasts expressing a disease-associated SQSTM1 mutation with a TIA1 variant had an increase in persistent SGs as compared with that seen in mCherry-SQSTM1-WT-expressing myoblasts (Figure 6D). To determine whether coexpression of...
Figure 6. SQSTM1 disease mutations alter SG kinetics and synergistically mediate myotoxicity with TIA1-N357S. (A) Bar graph showing the percentage of MEFs containing endogenous TIA1-positive SGs. MEFs were transfected with mCherry, mCherry-SQSTM1-WT, or 1 of 3 different disease mutations (PL, MV, or AX) incubated at 42°C for 1 hour and subsequently returned to 37°C for the indicated durations. Transfected cells were counted and are indicated as the total number of cells. Representative data were pooled from 3 independent experiments (n = 450–550). (B) Bar graph showing the percentage of fibroblasts containing TIA1/G3BP1-positive SGs from fibroblasts of control patients (fibroblast lines 112 and 409), patients carrying the TIA1-N357S variant (fibroblast lines 107 and 319), and a patient carrying both a SQSTM1-A390X mutation and a TIA1-N357S variant (fibroblast line 483) immediately following 0.5 mM AsIII treatment for 1 hour or following a 40-minute recovery. (C) Immunofluorescence images of patients’ fibroblasts detailed in B, immunostained with TIA1 (green) and G3BP1 antibodies (red) before, immediately following 0.5 mM AsIII treatment for 1 hour, and following a 40-minute recovery. DAPI nuclear staining is shown in blue. Scale bars: 5 μm. Representative data were pooled from 3 independent experiments (n = 120–150). (D) Bar graph showing the percentage of C2C12 myoblasts containing TIA1-positive SGs. C2C12 myoblasts were cotransfected with mCherry, mCherry-SQSTM1-WT, or mCherry-SQSTM1 with 1 of 3 different disease mutations (PL, MV, or AX) and GFP-TIA1-WT or 1 of 2 variants (EK or NS) incubated at 42°C for 1 hour and subsequently returned to 37°C for the indicated durations. (E) Bar graph of LDH release from C2C12 myoblasts similar to those in D, before HS and after 1 hour of HS, with an additional 1-hour recovery at 37°C. The absorbance of the samples was measured at 492 nm. The reference wavelength at 680 nm was measured. Representative data were pooled from 3 independent experiments (n = 150–200). Error bars represent the mean ± SEM. *P < 0.05, by 2-way ANOVA and 2-tailed Student’s t test.
SQSTM1-AX and TIA1-NS synergistically enhanced myotoxicity, we performed a lactate dehydrogenase (LDH) release assay on C2C12 myoblasts cotransfected with plasmids expressing mCherry-SQSTM1-WT or mCherry-SQSTM1-AX and GFP-TIA1-WT or GFP-TIA1-NS before HS and after 60 minutes of HS with an additional 60 minutes of HS recovery, a time point at which persistent SGs are present. Consistent with a synergistic effect, SQSTM1-AX– and TIA1-NS–expressing myoblasts had increased LDH release as compared with the SQSTM1-WT or TIA1-WT transfectants (Figure 6E).

Discussion

The present study identified 14 patients from 9 families with distal myopathy and RV-IBM pathology, who all carried a previously reported pleotropic mutation in SQSTM1 and a rare TIA1-N357S variant. These patients did not manifest other phenotypes associated with SQSTM1 mutations such as PDB, ALS, or FTD at the time of examination. Importantly, SQSTM1 and TIA1 accumulated with TDP-43 in patients’ muscle tissue, suggesting that they participate in the disease pathogenesis. While the connection between SG clearance and autophagic protein degradation has been previously suggested, the present study provides human genetic evidence for a pathologic interaction (27, 28). These data support the notion that inheritance of a TIA1 variant can shift the phenotypic spectrum of SQSTM1 mutations to myodegeneration.

Mutations in SQSTM1 were initially identified in patients with familial PDB and included the SQSTM1-P392L and c.1165+1 G>A splice acceptor mutations (12). Notably, the SQSTM1-P392L mutation was found in approximately 9% of patients with sporadic PDB, making it the most common genetic cause of the disease (12). Later reports identified other missense mutations in or truncations of the UBA domain of SQSTM1, including the M404V mutation as causative in familial and sporadic PDB (29). Subsequently, SQSTM1 mutations including the P392L and c.1165+1 G>A were identified in patients with familial ALS and/or FTD (13, 14, 35). In 2015, we described 3 patients who had distal myopathy and RV-IBM pathology with the SQSTM1 c.1165+1 G>A mutation (1). Since the same SQSTM1 mutation can generate distinct phenotypes in different patients, we suggested that SQSTM1-associated disease be termed multisystem proteinopathy type 4 (MSP4) (1). MSP defines a pleotropic genetic disease, in which a single gene mutation and mutation can manifest as distinct disease phenotypes that include PDB, RV-IBM, ALS, and FTD.

We previously reported a TIA1-E384K founder mutation as the cause of WDM, an autosomal dominant distal myopathy with RV-IBM pathology (6). The phenotype of patients with WDM is similar to that of the SQSTM1-TIA1 patients described in this report. WDM is a progressive, late-onset myopathy that typically manifests in the fifth decade. A very small number of WDM patients who are homozygous for the TIA1-E384K variant have an earlier onset and more rapid disease progression, suggesting that the TIA1-E384K mutation exerts a dose-dependent, dominant effect (36). Similarly, we identified 1 patient in our cohort with distal myopathy who was homozygous for the TIA1-N357S variant. This patient did not have a second mutation in SQSTM1. The TIA1-N357S variant was overrepresented in our myopathy cohort and was present in 20% of our distal myopathy patients. These data support the idea that the TIA1-N357S variant may itself be a risk factor for distal myopathy.

The findings in our study may relate to other forms of MSP. Specifically, mutations in VCP, a ubiquitin segregase necessary for autophagic protein degradation, were the first identified cause of MSP (originally termed IBMF, for inclusion body myopathy-associated with Paget’s disease of the bone and fronto-temporal dementia) (2). Recent studies confirm the original report that 90% of patients develop RV-IBM, 42% develop PDB, and 30% develop FTD, but also expand the degenerative phenotypes to include 9% of patients with ALS and 4% with parkinsonism (37). Why some patients with VCP mutations develop RV-IBM and others PDB is not clear, but as with our study, it probably relates to oligogenic inheritance. For example, patients manifesting with VCP-associated dementia are more likely to carry an APOE4 allele (38). Some VCP mutations, like the SQSTM1-P392L mutation have low MAFs in the general population. Rare variants in VCP and SQSTM1 are identified as overrepresented in large cohorts of patients with sporadic PDB, IBM, ALS, or dementia, suggesting that they may be risk factors for disease or have reduced penetrance (13, 14, 30, 39–43).

Digenic inheritance can manifest in several ways. For example, the inheritance of a second genetic variant can affect the primary gene’s mutant phenotype by modifying its severity or age of onset. Another example occurs when a single genetic mutation may have a reduced penetrance, and the inheritance of a mutation in a second gene unmasks the variable expressivity of the primary mutation. Examples of true digenic inheritance, in which the inheritance of 2 variants on different genes is necessary to manifest disease, are rare and challenging to prove. One recent example is found in some forms of facioscapulohumeral muscular dystrophy type 2 (FSHD2), in which a patient must inherit both a permissive D4Z4 allele and an SMCHD1 variant on different chromosomes (44). The strength of this example relates to its presence in multiple families and the convincing mechanistic interaction between the 2 alleles.

While autophagy has been implicated in SG clearance, this is the first report to our knowledge to demonstrate a role for SQSTM1 in SG dynamics. RNA-binding proteins such as TIA1 initiate granule formation via their LCDs by promoting reversible LLPS (45). Persistent SGs may occur when LLPS converts the LCD into an irreversible amyloid-like structure (20). Our data suggest that, while the TIA-EK and -NS variants promote phase separation, only the TIA1-EK variant enhances its amyloidogenic conversion. This may explain why heterozygous TIA1-E384K mutations lead to WDM, yet TIA1-N357S variants require a SQSTM1-mutant environment for penetrance. Loss of SQSTM1 or SQSTM1-mutant expression leads to the accumulation of degraded, ubiquitinated, and insoluble proteins (46). The presence of misfolded and aggregate-prone proteins increases SG formation and persistence in cell culture (32, 47). Likewise, we found that in the setting of SQSTM1-knockout or -mutant expression, TIA1-persistent SGs colocalized with aggregated proteins such as DRiPs and a C-terminal TDP-43 fragment. While it is possible that SQSTM1 directly shuttles ubiquitinated and aggregated TIA1 to the autophagosome, we propose an alternate model. Specifically, the presence of the SQSTM1 mutations leads to the cytosolic accumulation of aggregated proteins that then serve as a nidus for RNA granule conversion to an irreversible state.

The mechanism whereby disturbances in RNA granule dynamics and persistence of poorly dynamic SGs impair cell function in general or cause muscle degeneration in particular remains
unclear. One possibility is that disturbance of the SG dynamics results in the impairment of functions normally conducted within these complex, membrane-less organelles (e.g., remodeling of messenger ribonucleoprotein particles [mRNPs] or participating in intracellular signaling cascades). Alternatively, the condensed liquid environment of the SG may promote untoward fibrillization of RNA-binding proteins to produce insoluble, pathological species. Indeed, in vitro LLPS promotes a rapid fibrillization of RNA-binding proteins that occurs within the condensed liquid phase, resulting in the accumulation of potentially toxic species (20).

An enigmatic feature of the syndrome MSP and most of the constituent diseases (ALS, FTD, and RV-IBM) is the prominence of TDP-43 pathology, despite tremendous heterogeneity in its genetic etiology. Thus, mutations in genes as diverse as VCP, SQSTM1, C9orf72, HNRNPA1, HNRNPA2B1, TARDBP, and TIA1 culminate in highly similar histopathology, in which cytoplasmic deposition of fibrillar TDP-43 is a prominent feature. Notably, even when disease mutations occur in other RNA-binding proteins prone to fibrillization, such as TIA1, the histopathological picture is dominated by TDP-43 pathology (7). A likely explanation for this phenomenon is that there are differences in the stability of fibrils assembled from various RNA-binding proteins. Indeed, it was recently demonstrated that recruitment of TDP-43 to SGs results in an abrupt reduction in the mobility of this protein and conversion to an SDS-resistant, poorly soluble species, whereas other RNA-binding proteins recruited to the same SGs remain mobile and soluble (7).

Cytosolic TDP-43 accumulation has been shown to elicit cellular toxicity via several mechanisms including disruptions in RNA transport, splicing, and nucleocytoplasmic shuttling (48). Interestingly, autophagic inhibition leads to the cytosolic accumulation in TDP-43 (49). This effect also occurs in differentiated skeletal muscle, further connecting autophagic impairment with SG pathology (49). Interestingly, enhancing autophagy has been shown to be protective in the setting of TDP-43 accumulation (50).

MSP may represent an alternative manifestation of digenic inheritance. Specifically, a mutation on gene X (i.e., SQSTM1 or VCP) can lead to variable expressivity of multiple phenotypes (PD, ALS, FTD, or RV-IBM). Inheritance of a variant on gene Y (TIA1), while impenetrant alone, dictates the phenotypic expression of gene X (distal myopathy with RV-IBM pathology). This model explains the genetics of MSP but may also relate to the phenotypic penetrance seen within the ALS-FTD spectrum. In addition, our model supports a pathomechanistic connection between SG homeostasis and ubiquitin-mediated autophagic degradation.

**Methods**

**Genetic studies.** A cohort of 1,293 patients with presumed hereditary myopathy were sequenced using a targeted high-throughput sequencing panel called MYOcap. The panel covered the exons, as well as some 3′- and 5′-UTRs of selected genes either reported to cause muscle disease or to be functionally related to such genes (15). The MYOcap panel has been regularly updated, and samples of the cohort were sequenced with 4 versions covering 180, 236, 265, and 297 genes, respectively. The TIA1 and SQSTM1 genes were included in all versions. Specific probes were manufactured by Roche NimbleGen (SeqCap EZ Choice Library). DNA was extracted from blood by standard methods, and enrichment and sequencing were performed at the Institute for Molecular Medicine of Finland (FIMM), Biomedicum in Helsinki, Finland, and at the Wellcome Trust Centre for Human Genetics (WTCHG) in Oxford, United Kingdom, using the Illumina HiSeq1500 and HiSeq2000 platforms. The sequencing raw data were mapped against the human reference genome GRCh37/hg19. Data analysis was performed using an in-house pipeline as described earlier (15).

Indexed genomic DNA (gDNA) libraries were prepared from gDNA using a TruSeq DNA Preparation Kit (Illumina), and exome capture was done using a TruSeq Exome Enrichment Kit (Illumina) according to the manufacturer’s protocol. Sequencing was performed with 100-bp paired-end reads on a HiSeq2000 (Illumina). Reads were aligned to the human reference genome with NovoAlign or Burrows-Wheeler Aligner. Variants were called with SAMtools (http://samtools.sourceforge.net/) and annotated with SeattleSeq (http://snp.gs.washington.edu/SeattleSeqAnnotation138/). Coverage across genomic intervals was calculated using bedtools (http://bedtools.readthedocs.io/en/latest/). Genomic coordinates for regions targeted by the whole-exome capture kit were provided by Illumina. High-throughput sequencing results were verified by Sanger sequencing. Allele frequencies for the general population were taken from gnomAD (51).

**Protein purification, in vitro fibrillization, and phase diagram.** Recombinant DNA for TIA1 WT, N387S, and E384K constructs were cloned into the pET-Tet N-His SUMO Kan vector (Lucigen). Plasmids were chemically transformed into BL21 DE3 cells (Lucigen). Protein purification, in vitro fibrillization, and phase diagram protocols described in Mackenzie et al. (7) were followed. For the phase diagram, the spectrum of BSA (nonamyloid fibril-forming) was measured as a baseline. That baseline was subtracted from all the WT, E384K, and N357S spectra at each time point, respectively.

**Muscle pathology, reagents, and antibodies.** Frozen muscle sections were processed for routine histochemical analysis, including H&E, modified Gomori trichrome, combined succinate dehydrogenase–cytochrome oxidase, ATPase at pH 9.2, pH 4.3 and reduced nicotinamide adenine dinucleotide–tetrazolium reductase.

The following antibodies were used: anti-TIA1 polyclonal antibody (C-20; Santa Cruz Biotechnology; catalog sc-1751; 1:500 for WB, 1:100 for IF); anti-G3BP1 polyclonal antibody (ProteinTech; catalog 13057-2-AP; 1:100 for IF); anti-p62 polyclonal antibody (ProteinTech; catalog 18420-1-AP; 1:1,000 for WB and 1:100 for IF); anti-GFP polyclonal antibody (MilliporeSigma; catalog G1544; 1:500 for WB); anti-Ub monoclonal antibody (FK2, Biomol; catalog PW-8810; 1:500 for WB and 1:100 for IF); anti-Ub polyclonal antibody (Dako; catalog Z0458; 1:5,000 for WB and 1:100 for IF); and anti-GAPDH polyclonal antibody (Cell Signaling Technology; catalog 2118; 1:1,000 for WB). For the detection of endogenous proteins in patients’ muscle biopsies, the following antibodies were used for IF: anti-TIA1 polyclonal antibody (Abcam; catalog ab61700; 1:100) and anti-p62 polyclonal antibody (MilliporeSigma; catalog P0067; 1:100).

**Cell culture and transient transfection.** Fibroblasts were cultured in Fibroblast Basal Medium FGM-2 (Lonza; catalog CC-313) supplemented with FGM-2 SingleQuot Kit & Growth Factors (Lonza; catalog CC-4126), as recommended by the manufacturer, at 37°C and 5% CO2 in a humidified incubator. Immortalized control and p62−−MEFs were provided by M. Komatsu (Niigata University, Niigata, Japan). MEFs were maintained in DMEM (Gibco, Thermo Fisher Scientific; catalog 11965-084); 10% FBS (Atlanta Biologicals; S10350H); 50 μg/ml...
pennipicillin-streptomycin (MilliporeSigma; catalog P4333); 1% sodium pyruvate (Gibco, Thermo Fisher Scientific; catalog 11360070); and 1% nonessential amino acids (Gibco, Thermo Fisher Scientific; catalog 11440050) at 37°C in 5% CO₂. C2C12 cells were obtained from MilliporeSigma (catalog 91031101) and maintained in DMEM, 20% FBS, and 50 μg/ml penicillin-streptomycin. Transfection was performed with Lipofectamine 2000 (Life Technologies, Thermo Fisher Scientific; catalog 11668019) according to the manufacturer’s instructions. Twenty-four hours after transfection, cells were washed three times with ice-cold PBS. pDEST-mCherry-human p62 WT was a gift of Terje Johansen (University of Tromso, The Arctic University of Norway, Tromso, Norway) (46). pDEST-mCherry-human p62 P392L, M404V, and A390X were generated by mutagenesis in-house. GFP-human TIA1 WT (isoform A) has been previously reported, and GFP-human TIA1 E384K and N357S were generated by mutagenesis (7).

Immunocytochemistry and fluorescence microscopy. Cells were grown on glass coverslips prior to transfection with plasmid constructs. Twenty-four hours after transfection, cells were washed three times with PBS, fixed in 4% PFA for ten minutes, and permeabilized with 0.05% Triton X-100 in PBS for ten minutes. After washing three times with PBS, cells were blocked with 2% BSA in PBS for 30 minutes to 1 hour at room temperature (RT). Cells were stained with a primary antibody at 4°C overnight followed by washing 3 times with PBS. Cells were incubated with Alexa 555- or Alexa 488 Fluor–conjugated secondary antibody at RT for 1 hour and mounted with Mowiol media containing DAPI. Images of 10 random fields were taken with a ×20 objective using a Nikon Eclipse 80i fluorescence microscope. A blue channel was separated and used to count the total number of DAPI-stained cells in Figure 3B, Figure 5B, and Supplemental Figure 3B. Cells costained with both TIA1 (green) and G3BP1 (red) were counted in a merge channel. For Figure 2, C and D, and Figure 6A, individual cells shown in a green or red channel were considered GFP-TIA1− or mCherry-SQSTM1− expressing cells and counted as a total. For Figure 6D, C2C12 cells expressing both mCherry-SQSTM1 and GFP-TIA1 were counted as a total in each red or green channel, while C2C12 cells containing GFP-TIA1 puncta were counted in a merge channel. In Figure 3, C and D, individual SGs stained with TIA1 (green) were counted in a green channel as a total, while TIA1 SGs colocalized with SQSTM1 (red) were counted in a merge channel. For Figure 4, A and B, and Figure 4, C and D, individual endogenous TIA1 or GFP-TIA1 SGs (green) were counted as a total in a green channel, while TIA1 SGs colocalized with DRiPs (red) were counted in a merge channel. For Figure 5A, A and B, and Figure 4, B, individual TIA1 puncta (green) were counted as a total in a green channel, and TIA1/TDP-43-positive puncta were counted in a merge channel. Cells or individual SGs were counted using ImageJ software (NIH). Frozen muscle biopsy sections (8-μm thickness) were prepared on slides, fixed in 4% PFA for 15 minutes, and immunostained using a protocol similar to that for cultured cells.

**HS, inhibitor treatment, and DRiP labeling.** MEFs or C2C12 cells were incubated at 42°C with 5% CO₂ for 1 hour and returned to 37°C for the indicated durations (Figure 2, C and D; Figure 3, A and B; and Figures 4–6). For AsIII (MilliporeSigma; catalog 38150) treatment, control MEFs were treated with 0.5 mM AsIII for 1 hour, and AsIII-containing media were replaced at the indicated time point (Figure 2E legend). To label DRiPs, control or p62−/− cells were incubated at 42°C with 5% CO₂ for 1 hour and simultaneously treated with 2.5 μM OP-puromycin for 30 minutes. For recovery experiments, cells were returned to 37°C, and OP-puromycin-containing media were replaced for the indicated time (Figure 4 legend). Fixation and Click-IT reactions were performed with Alexa Azide 594 according to the manufacturer’s instructions (Life Technologies, Thermo Fisher Scientific; catalog C10399). MG132 (C2211) and BAFA (B1793) were purchased from MilliporeSigma. Control MEFs and p62−/− were treated with MG132 (20 μM) or BAFA (200 nM) for 1 hour at 37°C with 5% CO₂ after 1 hour of HS at 42°C.

Fluorescence recovery after photobleaching. Control MEFs were grown on 1.5 glass-bottomed 35-mm dishes (MatTek; P35G-1.5-10-C) and transfected with GFP-human TIA1 for 24 hours prior to imaging. Immediately before imaging, the medium was replaced with phenol red-free medium (Gibco, Thermo Fisher Scientific; catalog 21063029) containing 20% FBS, 50 μg/ml penicillin-streptomycin, 1% sodium pyruvate, and 1% nonessential amino acid. The live-cell samples were treated with 0.5 mM AsIII for 1 hour and placed on a heated chamber at 37°C with 5% CO₂. Imaging and photobleaching were performed with a ×40 oil objective using a Nikon A1Rsi confocal microscope. Before bleaching, the images of prebleached TIA1 aggregates were taken. A 488-nm laser was used to photobleach TIA1 aggregates for 500 ms. Immediately after bleaching, the images were collected every second for a total of 150 seconds as a post-bleached sample. The fluorescence intensities of post-bleached TIA1 aggregates (Ft) were individually measured. In the meantime, the fluorescence intensities of nonbleached TIA1 aggregates were measured as a reference control (Fref). Also, the fluorescence intensities of nonbleached and non-transfected background were measured as a background control (Fb). The photobleaching rate (r) was calculated by comparing the fluorescence of the reference before (Fref0) and after (Fref) photobleaching: \( r = \frac{F_{ref} - F_{ref0}}{F_{ref}} \). The average of TIA1 aggregates fluorescence intensities (F) in different cells (n ≥ 5 cells containing TIA1 aggregates) was calculated as follows: \( F = \frac{F_{t} - F_{b}}{r} \).

**LDH assay.** C2C12 cells were transfected with Cherry-p62 WT or AX along with GFP-TIA1 WT, -NS, or -EK 24 hours before the LDH assay. Cells were split into 96-well plates with 2 × 10⁵ cells per well, in triplicate. Cells were then incubated for 1 hour at 42°C in 5% CO₂ and returned to 37°C in 5% CO₂ for a 1-hour recovery. The LDH assay was performed according to the manufacturer’s instructions (Roche; catalog 04744926001).

**Statistics.** A 2-tailed Student’s t test between 2 groups and 2-way ANOVA between more than 2 groups were performed. For all tests, P values of less than 0.05 were considered statistically significant. Data are presented as the mean ± SEM.

**Study approval.** All evaluations and genetic studies were conducted with the approval of the Human Studies Committee of Washington University and the IRB of Helsinki University. Written informed consent was provided by all study participants, in accordance with Declaration of Helsinki principles.

**Author contributions**

YJL designed and performed experiments, analyzed results, and wrote the manuscript. CCW conceived and designed experiments, analyzed results, and wrote the manuscript. BU conceived and designed experiments, analyzed results, and wrote the manuscript. AE, TS, SP, MS, MJ, and PH designed studies and analyzed results, and wrote the manuscript. AE, TS, SP, MS, MJ, and PH designed studies and analyzed results, and wrote the manuscript. JPT designed experiments, analyzed results, and wrote the manuscript. CCW conceived and designed experiments, analyzed results, and wrote the manuscript. BU conceived and designed experiments, analyzed results, and wrote the manuscript. AE, TS, SP, MS, MJ, and PH designed studies and analyzed results, and wrote the manuscript.
results. SHR and AA designed experiments, analyzed results, and provided key reagents. MCM, DHJ, PM, PC, JR, CK, TK, SZ, CS, and HG provided key reagents and feedback on the manuscript.

Acknowledgments

CCW was supported by NIH (AG031867, AG042095, and AR068797); the Muscular Dystrophy Association; the Myositis Association; and the Hope Center for Neurological Disorders. BU was supported by the Academy of Finland; the Erikkö Foundation; the Sigrid Jusélius Foundation; the Folkhälso Institute of Genetics; and Tampere University Hospital Medical Research Funds. JPT was supported by the NIH (R35NS097974); St. Jude and the American Lebanese Syrian Associated Charities (ALSAC); and the Howard Hughes Medical Institute. We thank Helena Luque (the Folkhälso Institute of Genetics) for technical assistance.

Address correspondence to: Conrad C. Weihe, Department of Neurology, Hope Center for Neurological Diseases, Washington University School of Medicine, St. Louis, Missouri 63110, USA. Phone: 314.362.6981; Email: weihlc@wustl.edu.


